Alkermes PlcNASDAQ:ALKS
- LAST PRICE28.0150
- TODAY'S CHANGE (%)0.4850 (1.7617%)
- Bid / Lots28.0100/ 7
- Ask / Lots28.0200/ 4
- Open / Previous Close27.4300 / 27.5300
- Day Range
- 52 Week Range
- Volume393,458
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALKS |
|---|---|---|
| 09:32 ET | 6503 | 27.38 |
| 09:34 ET | 724 | 27.4 |
| 09:36 ET | 100 | 27.33 |
| 09:39 ET | 100 | 27.38 |
| 09:41 ET | 1300 | 27.59 |
| 09:43 ET | 10518 | 27.64 |
| 09:45 ET | 1040 | 27.64 |
| 09:48 ET | 323 | 27.66 |
| 09:50 ET | 757 | 27.665 |
| 09:52 ET | 1347 | 27.615 |
| 09:54 ET | 1001 | 27.59 |
| 09:56 ET | 5008 | 27.625 |
| 09:57 ET | 331 | 27.62 |
| 09:59 ET | 2383 | 27.63 |
| 10:01 ET | 226 | 27.65 |
| 10:03 ET | 800 | 27.71 |
| 10:06 ET | 750 | 27.765 |
| 10:08 ET | 500 | 27.82 |
| 10:10 ET | 894 | 27.83 |
| 10:12 ET | 800 | 27.86 |
| 10:14 ET | 400 | 27.825 |
| 10:15 ET | 200 | 27.81 |
| 10:17 ET | 840 | 27.765 |
| 10:19 ET | 1208 | 27.81 |
| 10:21 ET | 461 | 27.755 |
| 10:24 ET | 100 | 27.75 |
| 10:26 ET | 100 | 27.75 |
| 10:28 ET | 100 | 27.74 |
| 10:30 ET | 630 | 27.725 |
| 10:32 ET | 100 | 27.72 |
| 10:33 ET | 923 | 27.74 |
| 10:35 ET | 503 | 27.75 |
| 10:37 ET | 1000 | 27.82 |
| 10:39 ET | 823 | 27.775 |
| 10:42 ET | 200 | 27.83 |
| 10:50 ET | 1052 | 27.8 |
| 10:51 ET | 740 | 27.795 |
| 10:53 ET | 500 | 27.83 |
| 10:55 ET | 582 | 27.83 |
| 10:57 ET | 795 | 27.78 |
| 11:00 ET | 1714 | 27.755 |
| 11:02 ET | 909 | 27.81 |
| 11:04 ET | 311 | 27.84 |
| 11:06 ET | 2968 | 27.85 |
| 11:08 ET | 600 | 27.85 |
| 11:09 ET | 379 | 27.83 |
| 11:11 ET | 100 | 27.83 |
| 11:13 ET | 300 | 27.84 |
| 11:15 ET | 300 | 27.86 |
| 11:18 ET | 1000 | 27.88 |
| 11:20 ET | 600 | 27.87 |
| 11:24 ET | 305 | 27.87 |
| 11:26 ET | 200 | 27.87 |
| 11:27 ET | 914 | 27.85 |
| 11:29 ET | 1041 | 27.78 |
| 11:31 ET | 200 | 27.765 |
| 11:33 ET | 2550 | 27.8 |
| 11:36 ET | 100 | 27.81 |
| 11:38 ET | 500 | 27.8 |
| 11:40 ET | 1328 | 27.78 |
| 11:42 ET | 1900 | 27.78 |
| 11:44 ET | 1800 | 27.79 |
| 11:45 ET | 1300 | 27.82 |
| 11:47 ET | 4200 | 27.78 |
| 11:49 ET | 1833 | 27.79 |
| 11:51 ET | 3700 | 27.765 |
| 11:54 ET | 600 | 27.78 |
| 11:56 ET | 500 | 27.78 |
| 11:58 ET | 913 | 27.81 |
| 12:00 ET | 2419 | 27.79 |
| 12:02 ET | 1600 | 27.79 |
| 12:03 ET | 1205 | 27.8 |
| 12:05 ET | 949 | 27.77 |
| 12:07 ET | 300 | 27.745 |
| 12:09 ET | 1300 | 27.75 |
| 12:12 ET | 1902 | 27.72 |
| 12:14 ET | 2054 | 27.71 |
| 12:16 ET | 100 | 27.71 |
| 12:18 ET | 1118 | 27.73 |
| 12:20 ET | 1150 | 27.74 |
| 12:21 ET | 300 | 27.75 |
| 12:23 ET | 500 | 27.74 |
| 12:25 ET | 500 | 27.75 |
| 12:27 ET | 893 | 27.745 |
| 12:30 ET | 1137 | 27.78 |
| 12:32 ET | 3064 | 27.77 |
| 12:34 ET | 500 | 27.78 |
| 12:36 ET | 2400 | 27.79 |
| 12:38 ET | 428 | 27.79 |
| 12:39 ET | 100 | 27.79 |
| 12:41 ET | 1426 | 27.76 |
| 12:43 ET | 100 | 27.77 |
| 12:45 ET | 500 | 27.775 |
| 12:48 ET | 100 | 27.775 |
| 12:50 ET | 2307 | 27.775 |
| 12:52 ET | 3012 | 27.78 |
| 12:54 ET | 200 | 27.785 |
| 12:56 ET | 3744 | 27.82 |
| 12:57 ET | 1612 | 27.82 |
| 12:59 ET | 100 | 27.815 |
| 01:01 ET | 400 | 27.815 |
| 01:03 ET | 2356 | 27.83 |
| 01:06 ET | 500 | 27.825 |
| 01:08 ET | 500 | 27.83 |
| 01:10 ET | 2782 | 27.83 |
| 01:12 ET | 412 | 27.87 |
| 01:14 ET | 1560 | 27.83 |
| 01:15 ET | 500 | 27.835 |
| 01:17 ET | 100 | 27.835 |
| 01:24 ET | 766 | 27.845 |
| 01:26 ET | 798 | 27.84 |
| 01:30 ET | 300 | 27.84 |
| 01:32 ET | 2026 | 27.84 |
| 01:33 ET | 1210 | 27.83 |
| 01:35 ET | 751 | 27.83 |
| 01:37 ET | 529 | 27.83 |
| 01:39 ET | 100 | 27.83 |
| 01:44 ET | 2074 | 27.86 |
| 01:46 ET | 300 | 27.86 |
| 01:50 ET | 2052 | 27.82 |
| 01:51 ET | 299 | 27.83 |
| 01:53 ET | 200 | 27.82 |
| 01:55 ET | 24729 | 27.97 |
| 01:57 ET | 4019 | 27.94 |
| 02:00 ET | 700 | 27.955 |
| 02:02 ET | 3898 | 28 |
| 02:04 ET | 2075 | 27.98 |
| 02:06 ET | 683 | 27.97 |
| 02:08 ET | 400 | 27.99 |
| 02:09 ET | 4687 | 27.94 |
| 02:11 ET | 1423 | 27.98 |
| 02:13 ET | 2068 | 27.94 |
| 02:15 ET | 793 | 27.93 |
| 02:18 ET | 1733 | 27.9 |
| 02:20 ET | 800 | 27.9 |
| 02:22 ET | 1410 | 27.87 |
| 02:24 ET | 3221 | 27.855 |
| 02:26 ET | 2496 | 27.87 |
| 02:27 ET | 500 | 27.87 |
| 02:29 ET | 1371 | 27.88 |
| 02:31 ET | 1757 | 27.89 |
| 02:33 ET | 100 | 27.88 |
| 02:36 ET | 1106 | 27.91 |
| 02:38 ET | 400 | 27.91 |
| 02:40 ET | 1329 | 27.935 |
| 02:42 ET | 3274 | 27.96 |
| 02:44 ET | 200 | 27.96 |
| 02:45 ET | 259 | 27.96 |
| 02:47 ET | 400 | 27.98 |
| 02:49 ET | 1517 | 27.985 |
| 02:51 ET | 5740 | 28.01 |
| 02:54 ET | 4100 | 27.98 |
| 02:56 ET | 800 | 28 |
| 02:58 ET | 1349 | 28.015 |
Sep 25, 2024
Alkermes to Host Investor Event to Review Orexin Portfolio Strategy, from 8:00AM ET on Wednesday Sep 25, 2024 by Dow Jones
8:00AM ET on Wednesday Sep 25, 2024 by Dow Jones
Sep 23, 2024
Sep 16, 2024
DJ Alkermes Price Target Maintained With a $48.00/Share by Cantor Fitzgerald, from 11:30AM ET on Monday Sep 16, 2024 by Dow Jones
11:30AM ET on Monday Sep 16, 2024 by Dow Jones
Sep 13, 2024
Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards(R) Program, from 7:00AM ET on Friday Sep 13, 2024 by Dow Jones
7:00AM ET on Friday Sep 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Alkermes Plc | 4.6B | 10.5x | --- |
Exelixis Inc | 7.5B | 22.1x | -21.77% |
PTC Therapeutics Inc | 2.6B | -5.9x | --- |
Novavax Inc | 2.2B | -4.6x | --- |
P3 Health Partners Inc | 176.4M | -0.7x | --- |
Medpace Holdings Inc | 10.9B | 31.1x | +35.10% |
Company Information
Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Contact Information
- Headquarters
- Connaught House 1 Burlington Road, Dublin 4DUBLIN, Ireland D04 C5Y6
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Richard Pops
- Interim Chief Financial Officer, Chief Operating Officer, Executive Vice President, Interim Chief Accounting Officer, Chief Risk Officer
- Blair Jackson
- Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
- David Gaffin
- Executive Vice President, Research and Development and Chief Medical Officer
- Craig Hopkinson
- Senior Vice President, Chief Commercial Officer
- C.Todd Nichols
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.6B |
|---|---|
Revenue (TTM) | $1.5B |
Shares Outstanding | 164.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.42 |
EPS | $2.67 |
Book Value | $7.20 |
P/E Ratio | 10.5x |
Price/Sales (TTM) | 3.0 |
Price/Cash Flow (TTM) | 8.9x |
Operating Margin | 24.91% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
